Article
High prevalence of BRAFV600E in patients with cholestasis, sclerosing cholangitis or liver fibrosis secondary to Langerhans cell histiocytosis.
Pediatric blood & cancer - 1 Jul 2021
Carrere Xiomara, Pinto Nicolas, Gene Olaciregui Nagore, Galluzzo Laura, Rossetti Estefania, Celis Passini Veronica, Salvador Marcos Noelia, Chantada Guillermo, Braier Jorge, Lavarino Cinzia, Felizzia Guido
Abstract excerpt
Targeted therapies with MAPK inhibitors have proven to modulate the clinical manifestations of patients with Langerhans cell histiocytosis (LCH). We explored the presence of BRAFV600E mutation in our cohort of patients with LCH and cholestasis, sclerosing cholangitis, or liver fibrosis that presented resistance to chemotherapy. The BRAFV600E mutation was detected either in the diagnosis (skin and bone) or liver...
Topics
- Cholangitis, Sclerosing
- Cholestasis
- Histiocytosis, Langerhans-Cell
- Humans
- Liver Cirrhosis
- Mutation
- Prevalence
- Proto-Oncogene Proteins B-raf